Cancer Combo Collaborations Held Back By IP, Complexity – PSA Panelists
This article was originally published in The Pink Sheet Daily
Despite strides in recent years toward more cross-company collaborations to test cancer drugs in combination, most deals remain short-term, early-stage clinical partnerships, according to panelists at the Pharmaceutical Strategy Conference.
You may also be interested in...
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.